Government Contracts
Track federal awards and activity when available
Members-only details
HIND Earnings Date & History
Vyome Holdings Inc (NASDAQ NMS - GLOBAL MARKET) earnings schedule, consensus estimates and reported results for the last eight quarters.
Last updated Oct 29, 2026 at 9:29 AM ET
Vyome Holdings Inc
Pharmaceuticals
- Next earnings date
- Tuesday, November 24, 2026
- Reporting session
- Time TBD
- EPS estimate
- $-0.19
- Revenue estimate
- $0
Research beyond the earnings headline
What’s happening around HIND?
Congressional Trading
Review purchases and sales when available, transaction and disclosure dates kept separate
Members-only details
Insider Transactions
Company insider purchase and sale filings when available
Members-only details
Support & Resistance Levels
Key technical levels on an interactive chart
Members-only details
Previews show an example layout only, not data for HIND. Coverage varies by company.
HIND earnings history
| Report date | Quarter | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|---|
| Wednesday, August 12, 2026 | Q2 2026 | $-0.19 | $-0.10 | +48.4% | $26,960 |
| Tuesday, May 12, 2026 | Q1 2026 | $-0.18 | $-0.15 | +18.3% | $31,590 |
| Wednesday, March 18, 2026 | Q4 2025 | $-0.35 | $-0.21 | +40.0% | $36,550 |
What the market is watching in HIND's next report
- The full Earnings Read for this company: focus areas, peer read-through and prior-reaction context.
- Ticker Read combines trend, relative strength and catalysts in one research view.
- Scanners, daily catalyst context and the members-only Weekly Watchlist are included.
Free by email
Get the week's earnings by email
One free email each week: the reports that matter, when they land, and what the market is watching.
Frequently asked questions
Calendar data is provided for educational and research purposes only and is not investment advice. Release dates, times, estimates and results can change; always verify against the issuing company or agency.
HIND earnings discussion
Anyone can read. Any free Hyper Stocks account can join in.
Create a free account to join the discussion. Reading is open to everyone, commenting is free, no subscription needed.
Loading discussion…
Member comments are opinions from individual users, not Hyper Stocks research, and are never personalised investment advice.